PTC Therapeutics Insider Buys Shares; Analysts Set New Price Targets

Neil Gregory Almstead, the Chief Technical Operations Officer at PTC Therapeutics, Inc. (NasdaqGS: PTCT), purchased 5,323 shares of the company on June 24, 2026. He acquired these shares at an average price of $38.10, amounting to a total transaction value of $202,806. This purchase was not part of a pre-planned trading program.

Insider Buying and Selling at PTC Therapeutics, Inc.

On June 24, 2026, Neil Gregory Almstead, who serves as the Chief Technical Operations Officer, bought 5,323 shares of PTC Therapeutics at $38.10 per share. The total value of this transaction was $202,806, and it was not conducted under a Rule 10b5-1 plan. This insider activity was followed by additional transactions on June 25, 2026, where Almstead engaged in both buying and selling activities.

Other Institutional Activity in PTC Therapeutics

Several institutional investors have also adjusted their positions in PTC Therapeutics. BlackRock, Inc. increased its holdings by 169,652 shares, bringing its total to 12,948,717 shares valued at approximately $882.2 million, a 1.3% increase. Janus Henderson Group PLC significantly boosted its position by 2,342,101 shares, ending with 7,193,433 shares worth about $490 million, marking a 48.3% increase. Meanwhile, Vanguard Portfolio Management LLC initiated a new stake with 4,804,594 shares valued at $327.3 million. State Street Corp added 140,393 shares, raising its total to 4,346,519 shares valued at $296.1 million, reflecting a 3.3% increase.

PTC Therapeutics, Inc. Stock Up 20.5%

Shares of PTC Therapeutics traded near $84.51 on Saturday. The company, with a market cap of approximately $7.01 billion, has a forward P/E ratio of 30.36 and a beta of 0.549. Over the past 52 weeks, the stock has ranged from a low of $43.18 to a high of $87.50. The 50-day moving average is $72.01, while the 200-day moving average stands at $70.81. PTC Therapeutics maintains a current ratio of 2.44 and a quick ratio of 2.29.

Analysts Set New Price Targets

Analysts have recently adjusted their ratings and price targets for PTC Therapeutics. On June 9, 2026, Citigroup assumed coverage with a 'buy' rating and set a price target of $108. Jefferies upgraded its rating to 'buy' with an $85 target on May 27, 2026, and TD Cowen also upgraded to 'buy' with a target of $90 on May 8, 2026. The consensus among analysts is a 'buy' with an average target price of $93.93 based on 14 analyst opinions.

About PTC Therapeutics

PTC Therapeutics, Inc. is a biopharmaceutical company based in Warren, New Jersey. It focuses on discovering, developing, and bringing to market medicines for rare disorders affecting both children and adults. The company offers products like Translarna and Emflaza for Duchenne muscular dystrophy, Upstaza for AADC deficiency, and Evrysdi for spinal muscular atrophy. PTC Therapeutics, led by CEO Dr. Matthew B. Klein, collaborates with various organizations, including F. Hoffman-La Roche Ltd. and the SMA Foundation, to support its research and development efforts.